Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP9 | P55211 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799737 | 1.00 | TSHR (0.36) | TSHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL22799592 | 0.90 | TSHR (0.31) | TSHR | |
| SCHEMBL22799716 | 0.89 | TSHR (0.35) | TSHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL22799671 | 0.87 | TSHR (0.37) | TSHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL22799713 | 0.87 | TSHR (0.37) | TSHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL22799733 | 0.81 | TSHR (0.38) | TSHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL22799735 | 0.81 | TSHR (0.38) | TSHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL22800228 | 0.81 | CYP2A6 (0.40) | TSHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL22799849 | 0.81 | TSHR (0.38) | TSHRTDP2CASP3CASP7CASP9 | |
| SCHEMBL22799585 | 0.81 | CYP2A6 (0.40) | TSHRTDP2CASP3CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | TSHR 4556/4885TDP2 1199/4885CASP3 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.